Search

A combination of butorphanol-azaperone-medetomidine was used to immobilize four captive caribou (Rangifer tarandus granti) in Palmer, Alaska, US. The average induction time for this combination was 5:17±2:06 min. Inductions were smooth, and recoveries were excellent. This drug combination may provide an alternative to the use of potent opioids for immobilizing caribou.

Avaliou-se a eficiência do cateterismo posterior do plexo braquial em cães para promover bloqueio motor e sensitivo, por meio de três protocolos anestésicos. Foram utilizados nove cães, machos e fêmeas, sem distinção de raça e idade, com peso variando de 6 a 15kg, distribuídos em três grupos de três animais por grupo. Após a confirmação do correto posicionamento do cateter pela via posterior do plexo braquial por meio do exame radiográfico, foram aplicadas as medicações de acordo com os grupos. No grupo 1, a solução anestésica de bupivacaína 0,5% sem vasoconstrictor, na dose de 2mg.kg-1, foi usada isoladamente. No grupo 2, a solução anestésica de bupivacaína foi associada ao butorfanol na dose de 0,25mg.kg-1 . No grupo 3, o fentanil, na dose de 0,005mg.kg¹, foi associado à solução anestésica de bupivacaína. Não houve diferença estatística significante entre os grupos. Observou-se que a duração dos bloqueios motor e sensitivo foi clinicamente maior no grupo 2. O cateterismo posterior do plexo braquial permite a aplicação de fármacos mais próximos do plexo nervoso, promovendo analgesia complementar nos membros anteriores.

espanolEl picor o prurito es un efecto secundario muy molesto que aparece tras la administracion neuroaxial (epidural e intratecal) de farmacos opioides. A veces puede ser incluso mas desagradable que el propio dolor en si mismo. Tanto la prevencion como el tratamiento siguen siendo un desafio en la practica clinica asistencial de estos pacientes. Se han utilizado una gran variedad de medicaciones con diferentes mecanismos de accion enfocados en su prevencion y tratamiento, con resultados muy variables. El objetivo de este articulo ha sido revisar la literatura y resumir la evidencia actual de los mecanismos y los tratamientos farmacologicos disponibles para manejar el prurito inducidos por los opioides espinales. La fuente de articulos de esta revision se obtuvo a traves de PubMed, Medline y Scopus hasta diciembre del 2016. Dichos resultados de la busqueda se han limitado a los ensayos controlados aleatorios, revisiones sistematizadas y articulos de opinion de expertos en el tema. Los farmacos mas utiles son los antagonistas opioides mu, como naloxona, y los opioides mixtos agonistas kappa/antagonistas mu, como nalbufina y butorfanol, siendo estos ultimos capaces ademas de mantener la analgesia. Tambien han demostrado cierta eficacia, pero en menor grado, los antagonistas del receptor de la serotonina 5-HT3, como el ondasetron administrado profilacticamente, y los antagonistas de los receptores dopaminergicos D2, como el dehidrobenzoperidol. Finalmente el propofol a dosis subanestesicas y la profilaxis con mirtazapina y gabapentina via oral han sido utilizados con eficacia variable. EnglishThe itching or pruritus is a secondary effect very annoying that appears after the neuroaxial administration (epidural or intrathecal) of opioid drugs. Sometimes it can even be more unpleasant that the own pain by itself. Either prevention or treatment remains a challenge in the clinical practice of care for these patients. A wide variety of medications with different mechanisms of action have been used and focused in its management, with widely varying results. The objective of this article is to review the literature and summarize the current evidence of the mechanisms and pharmacological treatments available to handle pruritus induced by spinal opioids. The source of articles of this review was obtained through PubMed, Medline and Scopus until December 2016. These search results have been limited to the randomized controlled trials, systematized or comprehensive reviews and from opinion articles of experts in the subject. The most useful drugs are opioid mu antagonists, as naloxone, and mixed opioids kappa agonists /mu antagonists, as nalbuphine and butorphanol, the latter being able in addition to maintaining the analgesia. They have also shown some effectiveness, but to a lesser degree, from receptor antagonists of the serotonin 5-HT3, as ondasetron, administered prophylactically, and the antagonists of dopaminergic receptors D2, as dehidrobenzoperidol. Finally subanesthetic low dose of propofol and prophylactic oral mirtazapine and gabapentin have been used with medium results.

Visando observar os efeitos do butorfanol (B) na anestesia produzida pela associação de romifidina (R) e tiletamina-zolazepam (TZ), foram utilizados seis gatos adultos, de forma que todos animais receberam a associação de romifidina-tiletamina-zolazepam (grupo RTZ) ou a associação de romifidina-tiletamina-zolazepam-butorfanol (grupo RTZB). Os animais receberam em aplicação única, por via intramuscular, 7mg.kg-1 de tiletamina e 7mg.kg-1 de zolazepam e 40µg.kg-1 de romifidina (grupo RTZ) ou a mesma associação acrescida de 0,2mg.kg-1 de B (grupo RTZB). A freqüência cardíaca, freqüência respiratória, pressão arterial sistólica, diastólica e média por método não-invasivo oscilométrico, saturação de oxihemoglobina e temperatura retal foram avaliadas durante 120 minutos e comparadas aos valores basais. Os efeitos anestésicos foram caracterizados por meio de um sistema de escores. Outros dados como período de latência, período anestésico hábil e período de recuperação foram mensurados para efeito comparativo. Os períodos de latência e anestésico hábil foram significativamente mais prolongados no grupo RTZB. Ocorreu diminuição da freqüência respiratória no grupo RTZB, havendo decréscimo transitório no grupo RTZ. A freqüência cardíaca não variou no grupo RTZ até os 60 minutos e decresceu significativamente no grupo RTZB. Conclui-se que a associação RTZ produz anestesia com mínimos efeitos cardiovasculares e que a adição do butorfanol à associação prolonga o tempo anestésico hábil, além de proporcionar analgesia mais duradoura, mas provoca efeitos colaterais como decréscimo da freqüência cardíaca e da freqüência respiratória em gatos. The effect of butorphanol was investigated in six adult cats anesthetized with romifidine-tiletamine-zolazepam. Cats were given romifidine (40µg.kg-1) tiletamine (7mg.kg-1) and zolazepam (7mg.kg-1) (RTZ) intramuscularly, or RTZ and butorphanol (0.2mg.kg-1) (RTZB). Heart rate, respiratory rate, oscillometric systolic blood pressure, diastolic blood pressure and mean blood pressure, oxihemoglobin saturation and rectal temperature were determined for 120 minutes and compared to baseline values. Anesthetic effects were evaluated using a score system. Time of induction, anesthesia and recovery were also determined for comparison. Induction time and anesthetic time were significantly longer in RTZB. In the RTZB group a significant decrease in respiratory rate was observed while in the RTZ group this was transitory. Heart rate did not change in the RTZ group until 60 minutes and decreased significantly in the RTZB group from the time of injection. It is concluded that RTZ is an effective anesthetic combination with minimal cardiovascular side effects and that addition of butorphanol to this combination prolongs the anesthetic time and induces analgesia for a longer period, but causes a decrease in heart and respiratory rate in cats.

Butorphanol (Stadol, Bristol-Meyers Squibb, Princeton, NJ) is a synthetically derived opiate. As a nasal spray, it was approved for release in 1991 and was subsequently promoted as a safe treatment for migraine. Since then, there have been numerous reports of problems with butorphanol similar to those of any narcotic, especially dependence-addiction and major psychological disturbances. These problems have been documented by the Food and Drug Administration, but the information can be obtained only through the Freedom of Information Act. The experience with butorphanol indicates the need for physicians to have additional sources of information about drugs than are presently available.

The objective of this study was to determine whether administration of an analgesic to sows immediately after farrowing would allow them to lie more restfully. Sows lying on their pigs, causing them to be "crushed," is a major cause of pig mortality. Most deaths due to crushing occur during the first 3 d postpartum. For modern, lean-type sows, farrowing crates are relatively hard and unforgiving, even though they may be equipped with plastic-coated, expanded metal flooring. Indeed, many sows develop pressure sores on their shoulders, and this may contribute to the sows' discomfort. These sores may cause a sow to change position frequently to alleviate pain, thus increasing its chances of crushing pigs. Sixteen production sows were assigned to either a control group (C, n = 8) with litter size 11.71+/-.78 or an experimental group (B, n = 8) with litter size 11.63+/-1.22. Pigs born to C and B sows weighed 1.60+/-.04 and 1.37+/-.04 kg, respectively. The C sows were given no treatment, whereas the B sows were administered an i.m. injection of butorphanol tartrate at a dose of .15 mg/kg BW every 6 h until 3 d after farrowing. Data were collected on all sows using time-lapse photography (1 frame/.4 s) for a 3-d duration upon the initiation of farrowing. To assess the degree of comfort of each sow, body position changes were recorded when sows switched between lying, sitting, and standing. Data were analyzed by 12-h periods using Wilcoxon-Mann-Whitney equations. During the 72-h period, B sows tended to perform fewer position changes than C sows (P = .10). Specifically, position changes were fewer for B sows from 48 to 72 h postpartum (P.06). There were no differences in position changes between treatments from 0 to 48 h postpartum (P.50). There was no difference in the rate of crushing between treatments (C = 5, B = 5). The butorphanol did not seem to affect pig activity or normal behaviors or to create adverse effects, such as diarrhea. Although the sows given butorphanol showed a reduced number of position changes, the dose was intermediate, and a higher dose may have a greater effect. If pig mortality can be decreased, an analgesic protocol that is simple to administer and readily available to producers can be developed. Alternatively, using of more pliable flooring or an increase in sow body fat may allow sows to lie more stationary.